Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2600115890) titled 'Use of Telitacicept in Rescue Therapy for Rituximab (RTX)-Refractory/Relapsed Membranous Nephropathy (MN)' on Jan. 4.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: The First Affiliated Hospital of Zhengzhou University

Condition: Primary Membranous Nephropathy

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-01-04

Target Sample Size: Experimental group:50;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=295993

Disclaimer: Curated by HT Syndication....